Stockscreener 앱 받기
43.78
1.74%
0.73
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighHere's Why - MarketBeat
30,642 Shares in AnaptysBio, Inc. $ANAB Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Sells 27,809 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Will AnaptysBio Inc. stock deliver consistent dividendsWeekly Stock Report & Daily Volume Surge Trade Alerts - Newser
AnaptysBio stock hits 52-week high at 43.35 USD - Investing.com
AnaptysBio Shares Navigate Legal Headwinds Amid Strong Performance - AD HOC NEWS
How institutional buying supports AnaptysBio Inc. stockMarket Performance Recap & Smart Money Movement Alerts - Newser
Why AnaptysBio Inc. (AN6) stock could break out in 2025Market Activity Recap & Real-Time Market Trend Scan - Newser
The Bull Case For AnaptysBio (ANAB) Could Change Following Jemperli Legal Clash With GSK Subsidiary - Yahoo Finance
Virtus Investment Advisers LLC Sells 6,909 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Jemperli Royalty Dispute Could Be a Game Changer for AnaptysBio (ANAB) - Sahm
Is AnaptysBio Inc. (AN6) stock a top hedge fund pickQuarterly Growth Report & Real-Time Market Sentiment Reports - Newser
What sentiment indicators say about AnaptysBio Inc. stockPortfolio Return Report & Entry and Exit Point Strategies - Newser
ANAB: AnaptyBio Among Top Quality Stocks with High Returns - GuruFocus
AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says - MarketScreener
A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus - simplywall.st
Why AnaptysBio Inc. stock could rally in 2025Portfolio Update Report & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ
AnaptysBio FY2025 EPS Estimate Boosted by HC Wainwright - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio Files Legal Complaint Against GSK and Tesaro - TipRanks
AnaptysBio's complaint against Tesaro for breaching agreement was publicly filed on Nov 26SEC filing - marketscreener.com
AnaptysBio files lawsuit against Tesaro and GSK over license deal - StreetInsider
AnaptysBio, Inc Files Lawsuit Against Tesaro and GSK - TradingView
Behavioral Patterns of ANAB and Institutional Flows - news.stocktradersdaily.com
What drives AnaptysBio Inc AN6 stock priceEconomic Data Impact & Rapid Portfolio Appreciation - earlytimes.in
Anaptys Announces Participation in December Investor Conferences - The Manila Times
AnaptysBio, Inc. to Participate in Upcoming Investor Conferences Featuring Leadership Team Insights - Quiver Quantitative
Wedbush Backs AnaptysBio As Buyback Eases Investor Fears - Finimize
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighHere's What Happened - MarketBeat
AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat
HC Wainwright Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
DCF Advisers LLC Purchases 13,150 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (Nasdaq: ANAB) to join Piper Sandler and Evercore investor conferences - Stock Titan
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - Nasdaq
AnaptysBio stock hits 52-week high at 41.12 USD By Investing.com - Investing.com Nigeria
AnaptysBio stock hits 52-week high at 41.12 USD - Investing.com
GSK's TESARO sues AnaptysBio over alleged breach of cancer drug licence deal - Indian Pharma Post
ANAB: Wedbush Reiterates Outperform Rating and $50 Price Target - GuruFocus
Anaptys Announces $100 Million Stock Repurchase Plan - MarketScreener
AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says - marketscreener.com
AnaptysBio (ANAB) Analyst Rating Update: PT Lowered by HC Wainwr - GuruFocus
Is AnaptysBio Inc AN6 a good long term investmentShort Selling Opportunities & Double Or Triple Investment - earlytimes.in
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - MSN
Share Buyback Program Declared by AnaptysBio (NASDAQ:ANAB) Board of Directors - MarketBeat
AnaptysBio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Double Or Triple Capital - earlytimes.in
Legal Battle Puts AnaptysBio's Jemperli Royalties At Risk - Finimize
AnaptysBio (NASDAQ:ANAB) Shares Gap DownTime to Sell? - MarketBeat
AnaptysBio (ANAB) Price Target Increased by 22.51% to 58.23 - MSN
AnaptysBio sets $100M stock repurchase plan - MSN
AnaptysBio expands stock repurchase plan by $100 million - Investing.com Nigeria
Tesaro and AnaptysBio Enter Legal Battle Over Suspected Breach in Contract - Pharmaceutical Executive
UPDATE: GSK's Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues - BioSpace
European Equities Close Mixed in Friday Trading; Eurozone Composite PMI Continues to Expand - MarketScreener
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement - Investing.com Nigeria
GSK, Anaptysbio sue each other over Jemperli revenue - BioPharma Dive
AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement By Investing.com - Investing.com South Africa
0.79%
0.96%
자본화:
|
볼륨(24시간):